- Prescient Therapeutics has completed the manufacturing and delivery of crucial components for its unique next-generation OmniCAR platform.
- The production of binders for various cancer targets will enable Prescient’s research team to manufacture CAR-T cells for its three next-generation CAR-T programs.
- The oncology firm has also obtained delivery of lentiviral vectors to manufacture CAR-T cells expressing SpyCatcher.
- Prescient has developed OmniCAR as a platform that offers collaborations and third-party licensing opportunities.
In a milestone development regarding its innovative CAR-T cancer therapy programs, Prescient Therapeutics Limited (ASX:PTX) has announced that it has successfully completed the manufacturing and delivery of crucial components for its unique, next-generation OmniCAR platform.
The two novel components of the OmniCAR platform are: the SpyTagged binders and CAR-T cells expressing SpyCatcher. Notably, the SpyTag/SpyCatcher system is a crucial technology for binding of proteins. SpyCatcher is a genetically encoded protein, which reacts with SpyTag, a peptide of 13 amino acids, forming a bond between the two.
Delivery of binders and lentiviral vectors
The Company disclosed that a range of binders against various cancer targets, including CLL-1, CD33, EGFRviii, and Her2, have been manufactured by a US-based antibody manufacturer. More importantly, Prescient has incorporated SpyTag into these binders for the Company’s three next-gen CAR-T programs. SpyTag is necessary for covalent binding to immune cells (for instance, T-cells) in the OmniCAR system.
Source: PTX Update, 24 June 2021
Besides binders, Prescient has also obtained the delivery of lentiviral vectors. Lentiviral vectors are viruses which are used as gene delivery vehicle as they help in inserting, tweaking, or deleting a particular gene in a cell or organism.
As highlighted by PTX, lentiviral vectors are a rate-limiting step in CAR-T production and will be used to produce CAR-T cells expressing SpyCatcher.
Together, the SpyTagged binders and SpyCatcher CAR-T cells establish the basis for Prescient’s unique, modular OmniCAR platform.
The binders and lentiviral vectors have been delivered to the Peter MacCallum Cancer Centre, or Peter Mac, in Melbourne for construct assessment as well as in vivo and in vitro development.
How does Prescient’s OmniCAR work?
Prescient is developing OmniCAR programs for acute myeloid leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma (GBM) multiforme, the most widespread form of brain carcinoma.
After the formation of a fully armed and activated CAR-T cell, the cell activity can be controlled, and its target specificity can be switched when necessary.
Source: PTX Update, 24 June 2021
Additionally, Prescient has developed OmniCAR as a platform that permits collaborations and partnerships under licence with third parties willing to incorporate OmniCAR to improve their respective cell therapies.
The OmniCAR platform is developed based on technologies established at the University of Pennsylvania and the University of Oxford. Notably, the Company has secured global licensing rights for the commercialisation of those technologies.
Investor Briefing: The Company will host a briefing for PTX shareholders and investors on 1 July 2021 at 11:00 AM AEST. The event would discuss the progress with OmniCAR programs and the Peter Mac partnership.
To register for the event, click here.
Steven Yatomi-Clarke, the CEO and Managing Director of Prescient, commented-
Mr Steven also added that the research team of Prescient at Peter Mac had completed all the preparatory work in parallel. Besides, the delivery of the binders and vectors now empowers the team to progress the Company’s in-house next-generation cell therapies.
On 24 June 2021, PTX shares last traded at AU$0.200.
To know more about Prescient Therapeutics Limited, click here.
To stay updated with PTX company activities and announcements, please update your details on their investor centre.